$SAB Biotherapeutics (SABS.US)$ SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 Tuesday, 28th January at 7:00 am • SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose • Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes • Results will be presente...
$SAB Biotherapeutics (SABS.US)$there is a webinar happening at 8:00am EST. register here SAB BIO R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - LifeSci Event *not financial advice, be careful
$SAB Biotherapeutics (SABS.US)$this may have a catalyst today webinar @ 8:00am EST here SAB BIO R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - LifeSci Events **nfa
2
Report
Lnova
OP
:
“MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.”
$SAB Biotherapeutics (SABS.US)$ SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study. Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness. SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...
2
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
SAB Biotherapeutics Stock Forum
out alr
SAB Biotherapeutics Inc - SAB-142 Well-Tolerated, No Serum Sickness or Anti-Drug Antibodies
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
Tuesday, 28th January at 7:00 am
• SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose
• Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes
• Results will be presente...
*not financial advice, be careful
webinar @ 8:00am EST here SAB BIO R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - LifeSci Events
**nfa
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
Keep Watch 👀
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study.
Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness.
SAB-142 remains on track for a topline Phase 1 data readout by the end of the ye...
No comment yet